III.J.27. Medical Countermeasures Against Vesicant Agents. By FY96, exploit pathophysiology database and new technologies for prophylaxis, pretreatment, and antidote strategies which will provide significant protection against vesicant injury. By FY97, demonstrate efficacy of a vesicant countermeasure. Demonstrate by FY00, safety and efficacy of a candidate medical countermeasure sufficient for a Milestone 0 transition.
Supports: Development of Food and Drug Administration-licensed protectants, pretreatments, and therapies for vesicant agents; Program Manager-Soldier; Operational and Organizational Plans (Mar 87); Draft MNS (11 Sep 92); Joint Service Agreement (14 Dec 93)Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.
|STO Manager:||TSO:||TRADOC POC:|
|LTC D. Moore||MAJ Mark Seymour||Charles Campbell|